Review of BNP and NT-proBNP as prognostic biomarkers confirms their predictive value for adverse cardiovascular events across multiple clinical settings.
Key findingReview of BNP and NT-proBNP as prognostic biomarkers confirms their predictive value for adverse car
What the researchers found
Review of BNP and NT-proBNP as prognostic biomarkers confirms their predictive value for adverse cardiovascular events across multiple clinical settings.
Why it matters
Relevant to peptide therapeutics.
The numbers in context
Meta-analysis of studies examining BNP and NT-proBNP as prognostic markers for adverse outcomes, cardiovascular events, and mortality in HFpEF.
How the study worked
In publication.
Who was studied
HFpEF patients across observational studies and randomized controlled trials
What this study cannot tell us
In publication.
How to read the evidence
Based on design.
When this study was published
Published in 2025.
The bigger picture
Advances peptide evidence.
Questions still open
- Long-term implications?
- Evidence comparison?
- Next steps?
Common questions
What does this mean?
How reliable?
Read the original research
BNP and NT-proBNP as prognostic biomarkers for the prediction of adverse outcomes in HFpEF patients: A systematic review and meta-analysis.
Heart failure reviews, 30(1), 45-54
Citation
Ammar, Lama A; Massoud, Gaelle P; Chidiac, Charbel; Booz, George W; Altara, Raffaele; Zouein, Fouad A. (2025). BNP and NT-proBNP as prognostic biomarkers for the prediction of adverse outcomes in HFpEF patients: A systematic review and meta-analysis.. Heart failure reviews, 30(1), 45-54. https://doi.org/10.1007/s10741-024-10442-6